

Luis San

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5562942/publications.pdf>

Version: 2024-02-01

80
papers

3,341
citations

145106

33
h-index

169272

56
g-index

87
all docs

87
docs citations

87
times ranked

3673
citing authors

#	ARTICLE	IF	CITATIONS
1	Are plasma 25-hydroxyvitamin D and retinol levels and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?. <i>Psychiatry Research</i> , 2019, 273, 22-29.	1.7	2
2	Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review. <i>European Neuropsychopharmacology</i> , 2018, 28, 227-242.	0.3	24
3	PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. <i>European Neuropsychopharmacology</i> , 2018, 28, 710-718.	0.3	20
4	Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. <i>BMC Psychiatry</i> , 2017, 17, 126.	1.1	3
5	State of Acute Agitation at Psychiatric Emergencies in Europe: The STAGE Study. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2016, 12, 75-86.	0.6	41
6	Assessment and management of agitation in psychiatry: Expert consensus. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 86-128.	1.3	204
7	Adolescents and Dual Diagnosis in a Psychiatric Emergency Service. <i>Revista De Psicologia De La Salud</i> , 2016, 28, 71-9.	0.2	8
8	Clinical guideline for the treatment of dual pathology in the adult population. <i>Revista De Psicologia De La Salud</i> , 2016, 28, 3.	0.2	5
9	Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?. <i>Journal of Dual Diagnosis</i> , 2015, 11, 153-160.	0.7	19
10	Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 90-98.	1.2	18
11	Are women with a history of abuse more vulnerable to perinatal depressive symptoms? A systematic review. <i>Archives of Women's Mental Health</i> , 2014, 17, 343-357.	1.2	83
12	Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 485-490.	1.0	19
13	Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa. <i>Annals of General Psychiatry</i> , 2013, 12, 8.	1.2	11
14	Association of childhood adversities with the first onset of mental disorders in Spain: results from the ESEMeD project. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 371-384.	1.6	12
15	The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1421-1425.	1.0	24
16	Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. <i>Nordic Journal of Psychiatry</i> , 2013, 67, 22-29.	0.7	22
17	Factors associated with relapse in patients with schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 2-9.	1.2	44
18	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naïve patients with a first-episode psychosis. <i>Psychiatry Research</i> , 2012, 200, 693-701.	1.7	29

#	ARTICLE	IF	CITATIONS
19	Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 245-250.	2.5	16
20	Clinical meaningful outcomes in schizophrenia: remission and recovery. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2011, 4, 53-65.	0.2	7
21	Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study. <i>Schizophrenia Research</i> , 2011, 129, 169-171.	1.1	13
22	Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study. <i>European Neuropsychopharmacology</i> , 2011, 21, 861-866.	0.3	17
23	Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. <i>Patient Preference and Adherence</i> , 2011, 5, 601.	0.8	4
24	Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 18.	1.0	99
25	Resultados clínicos relevantes en esquizofrenia: remisión y recuperación. <i>Revista De Psiquiatría Y Salud Mental</i> , 2011, 4, 53-65.	1.0	16
26	Síntomas depresivos relacionados con la alteración de los ritmos circadianos. Concordancia entre la percepción de médicos y pacientes sobre prevalencia, impacto clínico y su respuesta a los fármacos antidepressivos actuales. <i>Revista De Psiquiatría Y Salud Mental</i> , 2011, 4, 19-27.	1.0	1
27	Immediate clinical assessment of medical intervention in schizophrenic patients admitted to an acute-care psychiatric unit: A retrospective, naturalistic and multicenter study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 196-203.	1.2	2
28	Psychometric Properties of the Young Mania Rating Scale for the Identification of Mania Symptoms in Spanish Children and Adolescents with Attention Deficit/Hyperactivity Disorder. <i>Psychopathology</i> , 2011, 44, 125-132.	1.1	10
29	Predictors of schizophrenia in patients with a first episode of psychosis. <i>Psychiatry Research</i> , 2010, 175, 11-14.	1.7	12
30	Clinical and serotonergic predictors of non-effective acute remitting psychosis in patients with a first episode psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 71-77.	2.2	10
31	Remission in schizophrenia: Results from a 1-year follow-up observational study. <i>Schizophrenia Research</i> , 2009, 108, 214-222.	1.1	50
32	Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission. <i>Schizophrenia Research</i> , 2009, 115, 58-66.	1.1	75
33	Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1463-1474.	1.4	20
34	Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. <i>European Psychiatry</i> , 2008, 23, 396-402.	0.1	95
35	Olanzapine Orally Disintegrating Tablet: A Review of Efficacy and Compliance. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 203-214.	1.9	35
36	Clinical characteristics of agitated psychotic patients treated with an oral antipsychotics attended in the emergency room setting: NATURA study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 127-133.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Remisión sintomática y funcionamiento social/profesional en pacientes con esquizofrenia tratados ambulatoriamente: prevalencia y asociaciones en un estudio transversal. <i>European Psychiatry</i> (Ed) 17, 431-434 (2007).	1.0	14
38	Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders. <i>European Addiction Research</i> , 2007, 13, 230-243.	1.3	35
39	Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients. <i>Psychiatry Research</i> , 2007, 153, 103-109.	1.7	18
40	Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study. <i>European Psychiatry</i> , 2007, 22, 490-498.	0.1	105
41	Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. <i>Human Psychopharmacology</i> , 2007, 22, 11-15.	0.7	27
42	The functioning of the Behavioral Activation and Inhibition Systems in bipolar I euthymic patients and its influence in subsequent episodes over an eighteen-month period. <i>Personality and Individual Differences</i> , 2007, 42, 1323-1331.	1.6	59
43	Reply to What Do We Know About Insulin Resistance and Glucose Metabolism in Patients With Schizophrenia Treated With Antipsychotics?. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 800-802.	1.1	1
44	A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. <i>European Psychiatry</i> , 2006, 21, 539-543.	0.1	40
45	Effect of 5-HT _{1A} Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients. <i>American Journal of Psychiatry</i> , 2006, 163, 1826-1829.	4.0	100
46	Mirtazapine: only for depression?. <i>Acta Neuropsychiatrica</i> , 2006, 18, 130-143.	1.0	12
47	Depression in Schizophrenia, Can it be Treated? A Review of the Evidence. <i>Current Psychiatry Reviews</i> , 2006, 2, 371-379.	0.9	2
48	Polymorphisms of the 5-HT _{2C} receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 195-200.	0.7	237
49	Pharmacological Management of Acutely Agitated Schizophrenic Patients. <i>Current Pharmaceutical Design</i> , 2005, 11, 2471-2477.	0.9	12
50	Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia. <i>Psychiatric Services</i> , 2004, 55, 997-1005.	1.1	69
51	Altered 5-HT _{2A} and 5-HT ₄ Postsynaptic Receptors and Their Intracellular Signalling Systems IP ₃ and cAMP in Brains from Depressed Violent Suicide Victims. <i>Neuropsychobiology</i> , 2004, 49, 189-195.	0.9	71
52	Reboxetine adjunct for partial or nonresponders to antidepressant treatment. <i>Journal of Affective Disorders</i> , 2004, 81, 67-72.	2.0	35
53	Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 349-356.	1.1	81
54	Insulin Resistance and Increased Leptin Concentrations in Noncompliant Schizophrenia Patients but Not in Antipsychotic-Naive First-Episode Schizophrenia Patients. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1335-1342.	1.1	141

#	ARTICLE	IF	CITATIONS
55	Uso combinado de marcadores serotoninérgicos de las plaquetas y escalas psicopatológicas como detección selectiva diagnóstica de un trastorno psicótico frente a uno depresivo. <i>European Psychiatry</i> (Ed Española), 2004, 11, 58-60.	0.0	0
56	Combined use of platelet serotonergic markers and psychopathological scales as diagnostic screening of a psychotic versus a depressive disorder. <i>European Psychiatry</i> , 2003, 18, 369-371.	0.1	2
57	Altered platelet serotonin 5-HT _{2A} receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients. <i>Psychiatry Research</i> , 2003, 118, 165-174.	1.7	26
58	Different distributions of the 5-HT reuptake complex and the postsynaptic 5-HT _{2A} receptors in Brodmann areas and brain hemispheres. <i>Psychiatry Research</i> , 2002, 111, 105-115.	1.7	11
59	Depression improvement with calcium heparin. <i>General Hospital Psychiatry</i> , 2002, 24, 450-451.	1.2	4
60	Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia. <i>American Journal of Psychiatry</i> , 2001, 158, 1149-1151.	4.0	258
61	Altered 5-HT _{2A} binding sites and second messenger inositol trisphosphate (IP ₃) levels in hippocampus but not in frontal cortex from depressed suicide victims. <i>Psychiatry Research - Neuroimaging</i> , 2000, 99, 173-181.	0.9	73
62	Human Pharmacology of 3,4-Methylenedioxymeth-amphetamine ("Ecstasy"): Psychomotor Performance and Subjective Effects. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 455-466.	0.7	185
63	PLATELET SEROTONERGIC BINDING SITES IN ALCOHOL-DEPENDENT PATIENTS. <i>Alcohol and Alcoholism</i> , 1999, 34, 726-732.	0.9	11
64	Immunological screening of drugs of abuse and gas chromatographic-mass spectrometric confirmation of opiates and cocaine in hair. <i>Biomedical Applications</i> , 1999, 724, 9-21.	1.7	43
65	Different regional distribution of the 5-HT reuptake complex, the 5-HT _{2A} receptors and their second messenger IP ₃ in human brain. <i>Neuroscience Research Communications</i> , 1999, 24, 107-115.	0.2	3
66	5-HT _{2A} receptors and their second messenger IP ₃ are only correlated in human brain and not in platelets. <i>Neuroscience Research Communications</i> , 1999, 25, 129-138.	0.2	5
67	Methadone and quality of life. <i>Lancet, The</i> , 1999, 353, 1101.	6.3	54
68	Characterization of the 5-HT ₄ binding site in human brain. <i>Journal of Neural Transmission</i> , 1998, 105, 575-586.	1.4	20
69	Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. <i>Drug and Alcohol Dependence</i> , 1998, 52, 193-200.	1.6	36
70	Monitoring Patterns of Substance Use in Drug-Dependent Patients. <i>Journal of Substance Abuse Treatment</i> , 1998, 15, 425-430.	1.5	5
71	Why is the administration route of heroine changing?. <i>Addiction</i> , 1997, 92, 688-689.	1.7	2
72	Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. <i>Addiction</i> , 1997, 92, 707-716.	1.7	85

#	ARTICLE	IF	CITATIONS
73	Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin-addicted patients. <i>Journal of Substance Abuse Treatment</i> , 1994, 11, 463-469.	1.5	18
74	Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990. <i>Addiction</i> , 1993, 88, 1341-1349.	1.7	46
75	Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification. <i>Drug and Alcohol Dependence</i> , 1993, 32, 281-286.	1.6	65
76	Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. <i>Addiction</i> , 1992, 87, 55-62.	1.7	50
77	Cocaine abuse among heroin addicts in Spain. <i>Drug and Alcohol Dependence</i> , 1991, 27, 29-34.	1.6	35
78	Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. <i>Addiction</i> , 1990, 85, 141-147.	1.7	57
79	Success and Failure at Inpatient Heroin Detoxification. <i>Addiction</i> , 1989, 84, 81-87.	1.7	36
80	A multicentre study to introduce naltrexone for opiate dependence in Spain. <i>Drug and Alcohol Dependence</i> , 1989, 23, 117-121.	1.6	26